))
5 Surprising Causes of Life Science Deal Failures
Manage episode 416232597 series 3506216
Contenido proporcionado por Darshan Kulkarni. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente Darshan Kulkarni o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
We discuss the five common reasons behind the failure of mergers, acquisitions and licensing deals in the life sciences industry.
Inadequate understanding of capability, where focusing solely on financials without comprehending the target company's regulatory and compliance processes leads to failure.
The side project dilemma, illustrated by Philip Morris' venture into pharmaceuticals, emphasizing the importance of aligning with core business objectives.
Clash of perspectives, exemplified by cultural and business differences between BioGene and Novartis, highlighting the necessity of alignment in strategic vision.
Low margins on generic drugs, as seen in Teva's acquisition of Actavis, revealing the
challenge of profitability in this sector.
Overpaying, stressing the significance of thorough due diligence to avoid paying more than a company's actual value.
For assistance with M&A due diligence, contact us at 302-252-6959.
67 episodios
Compartir
